inhibitor bcl family proteins induces regression solid tumours
proteins bcl family central regulators programmed cell death members inhibit apoptosis bcl-x-l bcl- overexpressed many cancers contribute tumour initiation progression resistance therapy bcl-x-l expression correlates chemo-resistance tumour cell lines reductions bcl increase sensitivity anticancer drugs enhance vivo survival development inhibitors proteins potential anti-cancer therapeutics previously explored- obtaining potent small-molecule inhibitors proved difficult owing necessity targeting protein protein interaction using nuclear magnetic resonance nmr-based screening parallel synthesis structure-based design discovered abt- small-molecule inhibitor anti-apoptotic proteins bcl- bcl-x-l bcl-w affinity two three orders magnitude potent previously reported compounds- mechanistic studies reveal abt directly initiate apoptotic process enhances effects death signals displaying synergistic cytotoxicity chemotherapeutics radiation abt exhibits single-agent-mechanism-based killing cells lymphoma small-cell lung carcinoma lines well primary patient-derived cells animal models abt improves survival causes regression established tumours produces cures high percentage mice
